Home Bratislava Medical Journal 2018 Bratislava Medical Journal Vol.119, No.4, p.229-233, 2018

Journal info


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564


Aims and Scope
Editorial Info
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.119, No.4, p.229-233, 2018

Title: Influence of morphine on TLR4/ NF-kB signaling pathway of MCF-7 cells
Author: S. Haghjooy-Javanmard, A. Ghasemi, I. Laher, B. Zarrin, N. Dana, G. Vaseghi


Morphine affects the risk of metastasis in cancer. The TLR4 gene promotes migration in adenocarcinoma cells. We investigated the effect of morphine on TLR4, MyD88 and NF-κ B-expression and migration. Migration of estrogen receptor-positive MCF7 breast cancer cells was studied after 24 and 48 hours incubation with morphine, with boyden chamber method. Morphine effect on TLR4, MyD88 and NF-κB mRNA expression was determined by quantitative Real-Time polymerase chain reaction. Migration was reduced at the doses of 0.5 and 5 µM (p < 0.05).

However, TLR4, MyD88 and NF-κBmRNA expression was decreased at the doses of 0.5, 5 and 500 µM. Morphine at the dose of 50 µM increased the expression of mentioned genes. MCF-7 cell line after 48 hours incubation with the dose of 0.5 µM morphine decreased the migration and at the dose of 0.5 µM down-regulated the mRNA expression of TLR4, MyD88 and NF-κB, however, the higher doses increased the expression of TLR4, MyD88 and NF-κB. Morphine affects TLR4expression in breast cancer cell, which depends on time and concentration (Tab. 1, Fig. 5, Ref. 24).

Keywords: MCF7, breast cancer, TLR4, MyD88, NF-κB, morphine
Published online: 09-Apr-2018
Year: 2018, Volume: 119, Issue: 4 Page From: 229, Page To: 233

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.